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Abstract
None of the polymorphic variants of the IL2RA gene found associated with Type 1 Diabetes (T1D) was shown to have a
functional effect. To test if the epigenetic variation could play a role at this locus, we studied the methylation of 6 CpGs
located within the proximal promoter of IL2RA gene in 252 T1D patients compared with 286 age-matched controls. We
found that DNA methylation at CpGs 2373 and 2456 was slightly but significantly higher in patients than in controls
(40.464.6 vs 38.365.4, p = 1.4E4; 91.462.8 vs 89.565.3, p = 1.8E-6), while other CpG showed a strictly comparable
methylation. Among 106 single nucleotide polymorphisms (SNPs) located in the neighboring 180kb region, we found that
28 SNPs were associated with DNA methylation at CpG2373. Sixteen of these SNPs were known to be associated with T1D.
Our findings suggest that the effect of IL2RA risk alleles on T1D may be partially mediated through epigenetic changes.
Citation: Belot M-P, Fradin D, Mai N, Le Fur S, Ze´le´nika D, et al. (2013) CpG Methylation Changes within the IL2RA Promoter in Type 1 Diabetes of Childhood
Onset. PLoS ONE 8(7): e68093. doi:10.1371/journal.pone.0068093
Editor: Massimo Pietropaolo, University of Michigan Medical School, United States of America
Received February 20, 2013; Accepted May 25, 2013; Published July 12, 2013
Copyright:  2013 Belot et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by ‘‘Alliance Diabe`te de Type 1 NovoNordisk-INSERM’’ program, Centre National de Ge´notypage (Evry), Association pour la
Recherche sur le Diabe`te, Programme Hospitalier de Recherche Clinique; by a grant from Association pour la Recherche sur le Diabe`te (ARD grant 2012 to DF),
and NovoNordisk France (‘‘Alliance’’ 2010–2013 to PB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Pierre.bougneres@inserm.fr
. These authors contributed equally to this work.
Introduction
Type 1 Diabetes (T1D) is characterized by an autoimmune
destruction of pancreatic b cells, a process in which autoreactive T
cells play a pivotal role [1–3]. IL2RA (IL-2 receptor a-chain,
CD25) is part of the high-affinity IL-2 receptor complex. IL2RA is
expressed constitutively on regulatory T cells, a population of T
cells that have a potent ability to suppress autoreactive T cells [4],
whereas is induced in other T cells. IL-2RA polymorphisms are
associated with T1D [5–8] and other autoimmune diseases such as
multiple sclerosis or rheumatoid arthritis [9,10].
Six positive regulatory region (PRR) and two negative
regulatory elements (NRE) located between 29 kb and +3.6 kb
around the transcriptional start site (TSS) are implicated in the
regulation of IL2RA expression in response to stimuli [11]. No
disease-associated SNPs have been reported in these regions.
However, each of these regions encompasses several CpGs known
to modify gene expression by altering the binding of transcrip-
tional proteins or by allowing the binding of methyl-CpG binding
domain proteins. DNA methylation changes have also been shown
to be important for the selective transcription of cytokine genes in
T cell subsets [12,13].
For these reasons, we studied the DNA methylation status of
6 CpGs located in the proximal promoter of IL2RA in T1D
patients together with the genetic variants located on the
surrounding 180 kb region of chromosome 10p15.1.
Results
DNA Methylation Specific Pattern across Tissues
The pattern of methylation in the whole blood cells (WBC) of
286 non-diabetic individuals (Table 1) showed important varia-
tions across the 6 studied CpGs located in the proximal promoter
region of the IL2RA gene (Figure 1). CpGs 2241, 2272 and
2356, close to the TSS, are almost unmethylated whereas the
more distant CpGs 2456 and 2459 are almost completely
methylated and CpG 2373 had an intermediate level of
methylation. This global pattern of methylation was also seen in
T1D patients, with subtle changes that will be discussed.
Methylation of the studied CpG was different in other tissues.
CpGs 2241, 2272 and 2356 showed an intermediate DNA
methylation level in liver, islet and peritoneum and remained
unmethylated in the thymus. CpG 2373 showed also a higher
methylation level in liver, islet or peritoneum than in WBC and
thymus. Methylation of CpGs 2456 and 2459 was comparable
across studied tissues. The level of methylation at CpGs 2459,
2456 and 2373 was lower in regulatory T cells.
Differential DNA Methylation is Related to T1D Status
The comparison of the 252 T1D patients with 286 age-matched
controls (Table 1) showed no T1D-related global directional
change in DNA methylation level that would affect all CpGs
equally (Table 1). There were, however, significant differences at
PLOS ONE | www.plosone.org 1 July 2013 | Volume 8 | Issue 7 | e68093
the specific CpG level. T1D patients had a higher level of CpGs
2373 and 2456 methylation than controls (p = 1.1024 and
p= 2.1026 respectively). Methylation levels of these two CpGs
were closely correlated (r = 0.44, p,3.10212, Figure 2), suggesting
a shared regulation of the methylation status of these CpG
residues. CpG2356 showed a slight and less significant increase in
percent of methylation in T1D group (p= 0.02), while methylation
of the three other CpGs was comparable with controls (Table 1).
We found no relationship between CpG methylation levels at
any position with age at diagnostic, current glycemic status
reflected by glycated haemoglobin (HbA1c) or T1D duration,
except for CpG 2241 that showed a slight increase of methylation
with diabetes duration (p = 0.004, Figure S1).
Influence of SNP Genotypes upon CG Methylation at the
IL2RA Locus
Among the analyzed 106 SNPs located within 180kb of the
chromosome 10p15.1, we found 32 SNPs that were associated
with DNA methylation of CpG 2241, 2272, 2356 and 2373
(Table 2). Twenty of these 32 SNPs were previously shown to be
associated with T1D by GWAS [5,14,15].
The association between rs6602398 and CpG -373 was the
strongest observed, with methylation of 42%, 40%, and 37% in
the GG, GT, and TT genotypes respectively. DNA methylation
level at CpG 2373 showed an association with 28/32 SNPs
located from 23 kb to 116 kb of this CpG, and 16/28 SNPs
previously found to be associated with T1D (Figure 3).
We observed no genetic-epigenetic statistical correlation
between SNPs and DNA methylation at CpGs 2456 and 2459.
Discussion
Using a candidate locus approach, the current study of CpG
methylation in the IL2RA promoter found that differences could
be detected in T1D patients. Two CpGs (2373 and2456) showed
an increased methylation in T1D patients compared to controls.
These significant differences were of small magnitude, but were in
the range previously reported for CpG in other gene promoters in
case control studies [16,17]. These methylation differences could
also be described in a categorical manner to simplify the
presentation of results: if classified as low (,1 Standard Deviation
(SD)), intermediate and high (.1SD), the methylation of CpGs
Figure 1. Schematic representation of DNA methylation levels in the proximal promoter of the IL2RA gene. Tissues come from different
non-diabetic controls: WBC (n = 286), liver (n = 7), peritoneum (n= 8), thymus (n = 16) and Langerhans islets (n = 7), regulatory T cells (n = 8).
doi:10.1371/journal.pone.0068093.g001
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2373 and 456 indicates that 4.6% of T1D patients versus 2.6% of
controls were in the upper category.
It was interesting to see that DNA methylation at CpG 2373
was correlated with 16 SNPs located at the IL2RA locus and
previously known to be associated with T1D [5,14,15].
The most significant association with CpG 2373 methylation
was seen for rs6602398 and rs4749926 (6.3E-05) that are both
located on intron 1. The IL2RA region encompasses large blocks of
linkage disequilibrium and it is possible that part of the genetic-
epigenetic associations observed is supported predominantly by
only a few tag SNPs. These associations allow to postulate the
existence of short distance genetic-epigenetic interactions resem-
bling the allele-specific methylation phenomenon reported at the
INS [16] or FTO locus [18]. Our observation is consistent with the
fact that loci harboring genetic variants that influence methylation
state, called methylation quantitative trait loci (methQTL) [19–
22], are known to be preferentially located in cis, outside CpG
islands and within a variable distance from CpG sites that averages
about 81 Kb [19].
Among the SNPs associated with CpG2373 methylation was
the rs2104286 variant (p = 2.9E-9), located in the 59end of the long
intron 1, that is the third independent IL2RA marker of T1D [23].
The odds ratio for T1D is 1.57 (CI 1.25–1.99) for AA
homozygotes at this SNP [23]. In our T1D cohort, rs2104286
AA carriers showed a 4% decrease in DNA methylation level in
CpG 2373 compared to GG carriers, with an intermediate level
for heterozygotes.
The two other SNPs that tag the first and the second T1D-
associated haplotypes are rs12722495 (not available in our
genotyping arrays) and rs11594656 that shows a strong association
with the methylation of CpG 2373 (p= 2.7E-5). Homozygote risk
allele carriers are more methylated at CpG 2373 than other
homozygotes or heterozygotes. The finding of a link between
genetic variants and epigenomic marks in T1D patients at the
IL2RA locus may provide a more general example of how genetic
and epigenetic variation can be related. This may help our future
understanding of the ‘‘missing heritability’’ enigma seen with
many genome wide association studies of multifactorial traits or
diseases, if it proves true that SNPs are only the markers that tag
neighboring epigenomic variations. According to this view, certain
SNPs showing strong statistical association with complex diseases
may not have any functional effects per se, but may be associated
with epitypes that have functional effects on gene expression. It
could be the case of rs11594656, where carriers of risk alleles are
more methylated and leading probably to less expression of IL2RA
gene.
According to our results in various tissues, the IL2RA promoter
region could be defined as a T-DMR (tissue-specific differentially
methylated region). T-DMRs are known to be involved in the
expression of tissue-specific genes as well as of key transcription
factors that govern transcription networks and tissue specificity
[24–30]. Peripheral blood being the only readily accessible tissue
sample for epidemiological studies, initial reports indicated that
DNA methylation measured in WBC may in some instances be
informative when tissues where the disease originates are not
available [31–33]. In this respect, most interesting cells to study the
methylation of the IL2RA gene promoter are regulatory T cells in
which IL-2 signaling seems to be a major effector in the
pathophysiology of T1D [34]. However, since T cells represent
40–60% of WBC and regulatory T cells expressing IL2RA only
Table 1. Main characteristics and CpG methylation levels in
the IL2RA promoter of T1D patients and age-matched non-
diabetic controls.
T1D Patients Controls pvalue
N 252 286
Sex (M/F) 132/120 130/156
Current age (yrs) 11.4564.13 11.0863.09 0.19
BMI (kg/m2) 18.6763.07 21.6369.51 0.86
Age at clinical onset
(yrs)
6.2263 – –
Diabetes Duration 5.2463.71 – –
Hba1c 8.0961.32 – –
CpG-241 9.7461.91 9.9462.72 0.71
CpG-272 1.761.79 1.9262.02 0.38
CpG-356 6.2461.27 5.9462.11 0.017
CpG-373 40.3864.64 38.3465.46 1.4.1024
CpG-456 91.4362.77 89.565.3 1.79.1026
CpG-459 82.3264.5 82.3464.57 0.82
Results are expressed as mean 6 sd.
doi:10.1371/journal.pone.0068093.t001
Figure 2. Correlation matrix of the methylation values (%) at the IL2RA promoter CpG sites in T1D patients (R in bold, p-value
below).
doi:10.1371/journal.pone.0068093.g002
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10% of peripheral CD4+ and ,1% of CD8+ [35], this was beyond the reach of our study. To get IL2RA expressing cells, large
Table 2. SNPs associated with DNA methylation at IL2RA promoter locus.
SNP position (hg18) p-value FDR Associated CpG GWAS p-value*
rs942201 chr10:6,126,298 0.0008 0.05 2272 1.1E-7
rs10905669 chr10:6,132,099 1.4E-03 4.9E-02 2272 5.8E-9
rs8177775 chr10:6,052,396 6.2E-04 2.0E-02 2241 0.05
rs8177772 chr10:6,055,063 6.2E-04 2.0E-02 2241 0.05
rs6602360 chr10:6,069,732 0.006 0.02 2373 1.2E-4
0.002 0.02 2241
rs7911500 chr10:6,077,732 0.002 0.01 2373
rs7898880 chr10:6,077,559 0.001 0.008 2373 1.0E-4
rs10795737 chr10:6,089,350 3.5E-05 0.0007 2373
rs12722588 chr10:6,100,439 0.003 0.01 2373
rs7900744 chr10:6,105,617 0.002 0.009 2373 4.8E-3
rs2025345 chr10:6,107,694 3.4E-05 0.0007 2373 0.01
0.0004 0.02 2241
rs12722561 chr10:6,109,899 0.0001 0.002 2373
4.6E-04 2.4E-02 2356
0.002 0.02 2241
rs7910961 chr10:6,117,802 0.001 0.007 2373 0.02
rs12722523 chr10:6,118,396 0.0003 0.003 2373
0.002 0.02 2241
rs7100984 chr10:6,118,545 0.0007 0.004 2373
rs7072398 chr10:6,119,852 0.0005 0.004 2373
rs12722515 chr10:6,121,236 0.0003 0.003 2373
0.002 0.02 2241
rs4749924 chr10:6,122,402 0.002 0.008 2373 5.8E-4
rs6602398 chr10:6,122,959 5.9E-07 6.3E-05 2373 9.0E-5
7.5E-04 0.02 2241
rs4749926 chr10:6,125,318 1.2E-06 6.3E-05 2373 6.6E-3
1.3E-03 4.9E-02 2272
1.0E-03 0.02 2241
rs791587 chr10:6,128,705 4.7E-06 0.0002 2373
0.005 0.04 2241
rs791589 chr10:6,129,577 0.002 0.009 2373 0.03
0.001 0.02 2241
rs2104286 chr10:6,139,051 0.0002 0.003 2373 2.9E-9
1.2E-03 0.02 2241
rs7090512 chr10:6,150,835 0.0001 0.002 2373 1.9E-4
rs4749955 chr10:6,158,672 0.0008 0.005 2373 1.4E-3
rs11594656 chr10:6,162,015 0.0007 0.004 2373 2.7E-5
rs6602437 chr10:6,170,083 0.0003 0.003 2373 2.6E-3
1.3E-03 0.05 2356
rs10905806 chr10:6,192,316 0.001 0.008 2373 0.03
rs6602450 chr10:6,193,303 0.0003 0.003 2373
rs4749997 chr10:6,201,787 0.0004 0.003 2373
rs7905816 chr10:6,209,278 0.002 0.01 2373
rs4750005 chr10:6,209,691 0.002 0.009 2373 4.1E-3
2.3E-04 2.4E-02 2356
*p-value from Todd et al. 2007, Barrett et al. 2009 and Bradfield et al. 2011.
doi:10.1371/journal.pone.0068093.t002
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amounts of WBC can be freshly sorted, but this needs exceedingly
large blood sample not accessible in clinical research in children or
adolescents and was not feasible from our preexisting DNA bank.
This is why, we confined our study to a subset of 8 healthy persons,
in whom we found that the level of DNA methylation in the
IL2RA promoter of regulatory T cells was lower than in other
Figure 3. Association results for the IL2RA region and CpG 2373. Manhattan plot represented p-values of Wald test based on linear
regression model (for each SNP, association test performed in plink which compares the quantitative phenotype means for three genotypes). The red
horizontal line represents the significance threshold of P = 4.761024.
doi:10.1371/journal.pone.0068093.g003
IL2RA CpG Methylation in Type 1 Diabetes
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WBC while being correlated with methylation in other blood cells
(figure S2). Whether this has a functional meaning cannot be
known from the current data. IL2RA is also expressed in a variety
of hematopoietic cell types, including activated T and B-
lymphocytes [36,37], NK (Natural Killer) cells [38–40], monocytes
[41,42] and a subset of dendritic cells [43,44].
In conclusion, the picture of genetic and epigenetic variation at
a T1D risk locus was shown by the current study to be both
entangled and complex. A given risk allele of a T1D associated
SNP is associated with increased methylation at a risk CpG, while
another risk allele of another T1D-associated SNP is associated
with decreased methylation. The overall level of methylation of the
risk CpG being increased in T1D patients, it is clear that the
genetic influence of the studied SNPs was not the sole factor that
could explain the changes in methylation observed in the T1D
patients. Only 1.7% of the variance of methylation at CpG 2373
could be attributed to rs2104286 and 4.6% to rs11594656. This
leaves a large contribution to influences from other genetic
variants or environmental factors shaping the methylation of CpG
throughout development. We do not think that the observed
methylation changes in T1D could be attributed to the disease
status, since they were independent from diabetes duration or
HbA1c, although subtle T1D-associated environmental factors
acting for example through dietary changes could be important in
determining DNA methylation level in specific positions (il faudrait
une ref indiquant un exemple de cette affirmation).
Materials and Methods
Participants
Whole blood cell samples were obtained from 252 patients and
286 controls were randomly extracted from the ISIS-Diab cohort
[16]. Patients and controls were included in the study according to
the French bioethics law. Families were carefully informed and
signed a detailed informed consent. Ethical approval for the study
was given by the Ethical Review Board of Ile de France (DC-2008-
693 NI 2620, CPP) and CNIL (DK-2010-0035).
Tissues
Samples from human liver (n = 7), peritoneum (n= 8), thymus
(n = 16) and Langerhans islets (n = 7), were provided by F. Pattou
and J. Kerr-Conte (UMR1011, U859, Lille). Each tissue comes
from a different person.
Isolation of Regulatory T cells
Human CD4+CD25+ T cells were isolated from 50 ml of
peripheral blood of 8 randomly chosen healthy blood donor
volunteers using density gradient centrifugation (Lymphocytes
separation medium, Eurobio) and purified by Human
CD4+CD25+ regulatory T Cell Isolation Kit according to
manufacturer’s instructions (Miltenyi). Briefly, CD4+ T cells were
negatively selected from the total PBMCs. Positive selection with
anti-CD25 magnetic microbeads was then used to separate the
negative CD4+CD252 T cell fraction from the CD4+CD25+ T
cells. Cells were applied to a second magnetic column, washed and
eluted again. This procedure led to the complete positive selection
of CD4+CD25+ T cells. Genomic DNA was extracted using
Gentra Puregene DNA isolation kit (Qiagen).
Isolation of Genomic DNA and Bisulfite Genomic
Conversion
Nucleic acids were extracted from whole blood cells (WBC) or
tissue samples using the phenol chloroform method. Genomic
DNA was treated with EZ-96 DNA Methylation-Gold Kit,
according to manufacturer’s protocol (Zymo Research Corpora-
tion).
Pyrosequencing
We PCR-amplified the bisulfite treated genomic DNA using
unbiased primers (sequences on request) and performed quanti-
tative pyrosequencing. Pyrosequencing was performed using a
PyroMark Q96 ID Pyrosequencing instrument (Qiagen). Pyrose-
quencing assays were designed using MethPrimer (http://www.
urogene.org/cgi-bin/methprimer/methprimer.cgi). Briefly,
200 ng of genomic DNA was treated with EZ DNA Methyla-
tion-Gold Kit and amplified. Biotin-labeled single stranded
amplicons were isolated according to protocol using the Qiagen
Pyromark Q96 Work Station and underwent pyrosequencing with
0.5mM primer. The percent methylation for each of the CpGs
within the target sequence was calculated using PyroQ CpG
Software (Qiagen).
Genotyping and Quality Control
Genotyping was attempted for 252 T1D samples on the
Illumina HumanHap300 array and the Illumina Human610-
Quad BeadChips at the Centre National de Ge´notypage (CNG,
France). Standard quality control procedures were applied. Briefly,
genotype data were retained in the study for samples that had been
successfully genotyped for .95% of the SNP markers. SNPs with
call rates of ,98%, with MAF ,2% or showing departure from
Hardy-Weinberg equilibrium in the control population (P,1023)
were excluded. For our study, we selected polymorphisms located
on chromosome 10, from 6,030,000 to 6,210,000 bp (Hg18),
corresponding to 106 SNPs.
Statistical Analysis
Differences in DNA methylation of the IL2RA promoter
between T1D and non-diabetic controls were analyzed using
non-parametric Wilcoxon rank sum test. Correlations were
calculated as adjusted R square that measures the proportion of
the variation in the independent variable accounted for by the
explanatory variables. The analysis of differences in DNA
methylation of the IL2RA promoter according to genotypes was
performed in PLINK. For each SNP, we compared the
methylation mean for the three genotypic states using the Wald
test statistic, based on a linear regression model, to generate a p-
value. Associations were considered significant when p-val-
ue,0.05/106= 4.7E-04. The results were visualized as a Man-
hattan plot. Methylation analyses adjusted for age were conducted
using logistic regression. Results are expressed as mean 6 sd. All
statistical analysis were conducted using R2.14.2.
Supporting Information
Figure S1 Lack of correlation between age at diagnos-
tic, Hba1c and diabetes duration and IL2RA promoter
methylation in T1D patients. Only CpG 2241 showed a
slight trend with diabetes duration (p= 0.004).
(TIF)
Figure S2 Correlation between IL2RA promoter meth-
ylation in regulatory T cells and other blood cells from 8
healthy individuals. Only CpG 2356 showed a significant
correlation however, all other CpG seemed correlated but failed to
reach the significativity because of the weak number of
participants.
(TIF)
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Table S1 List of the 77 diabetic centers by alphabetic
order participating to the ISIS-DIAB network.
(DOCX)
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